← Back to Clinical Trials
Recruiting NCT06923046

NCT06923046 Implementation of Team Clinic for Type 2 Diabetes (TCT2)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06923046
Status Recruiting
Phase
Sponsor Children's Hospital Los Angeles
Condition Type 2 Diabetes
Study Type INTERVENTIONAL
Enrollment 160 participants
Start Date 2025-08-14
Primary Completion 2027-05-31

Eligibility & Interventions

Sex All sexes
Min Age 12 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Standard of CareShared Medical Appointments

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 160 participants in total. It began in 2025-08-14 with a primary completion date of 2027-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if shared medical appointment is an acceptable way to deliver care to youth with type 2 diabetes. The main question\[s\] it aims to answer are: * Is shared medical appointments an acceptable care delivery model for this population? * Does shared medical appointment improve psychosocial outcomes for this population? Participants will attend quarterly clinic appointments and group activities and take surveys. Researchers will compare this intervention to standard of care.

Eligibility Criteria

Patient/AYA Participants Inclusion Criteria: * Receives care for type 2 diabetes at either CHLA or UCSF * English speaking youth * Youth prescribed medication for type 2 diabetes * English or Spanish speaking caregivers * Age 12 to 18 years old at the time of enrollment * Willingness to attend clinic visits and participate in group session (if randomized to Team Clinic), complete surveys Exclusion Criteria: * Participants who are non-verbal or unable to participate in group activities and discussions * Pregnancy * Inability or unwillingness of individual or legal guardian/representative to give written informed assent/consent Caregiver/Parents Participants Inclusion Criteria: * Has a child between the ages of 12 and up to 18 at the time of enrollment who receives care for T2D in the endocrinology clinic at CHLA. The child must provide consent/assent to participate as a youth participant. * Speaks English of Spanish. Over 95% of our T2D population speaks one of those two languages. Our facilitator will be bilingual in English and Spanish. It is not feasible for the facilitator to also speak another language. Having a language interpreter for discussion groups will affect the dynamics and flow of the group session * Willingness to participate in group session (if their child is randomized to Team Clinic) and complete surveys. Exclusion Criteria: -Inability or unwillingness of individual to give written informed consent

Contact & Investigator

Central Contact

Fatima Aguilar

✉ faguilar@chla.usc.edu

📞 323-361-4606

Principal Investigator

Lily Chao, MD

PRINCIPAL INVESTIGATOR

Children's Hospital Los Angeles

Frequently Asked Questions

Who can join the NCT06923046 clinical trial?

This trial is open to participants of all sexes, aged 12 Years or older, up to 18 Years, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06923046 currently recruiting?

Yes, NCT06923046 is actively recruiting participants. Contact the research team at faguilar@chla.usc.edu for enrollment information.

Where is the NCT06923046 trial being conducted?

This trial is being conducted at Los Angeles, United States, San Francisco, United States.

Who is sponsoring the NCT06923046 clinical trial?

NCT06923046 is sponsored by Children's Hospital Los Angeles. The principal investigator is Lily Chao, MD at Children's Hospital Los Angeles. The trial plans to enroll 160 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology